Pharmaceutical Technology

MAY 4, 2023

Forge Biologics and global life sciences company Labcorp have announced a strategic adeno-associated virus (AAV) gene therapy development and manufacturing collaboration. This will improve accessibility to services for AAV-mediated gene therapy programmes.

Gene Therapy 256

Gene Therapy Gene Development Manufacturing 256

Pharmaceutical Technology

APRIL 3, 2023

The deal will see Polyplus join the German life science group’s portfolio allowing the latter to leverage expertise in transfection reagents and plasmid DNA for gene therapy. Polyplus, based in Strasbourg, France, produces key components in the production of viral vectors used in cell and gene therapies.

Gene Therapy 246

Gene Therapy Gene DNA Reagent 246

Drug Discovery World

SEPTEMBER 4, 2023

AviadoBio, a gene therapy company developing medicines for neurodegenerative disorders, will establish laboratory and office presence at the Innovation Centre. Kadans and Canary Wharf Group are also progressing their joint venture to develop an GIA commercial health and life sciences building, the largest in Europe, on the 3.3-hectare

Life Science 59

Life Science Gene Therapy Genome Genomics 59

Pharmaceutical Technology

MAY 24, 2023

Forge Biologics has joined the public-private collaboration, the Bespoke Gene Therapy Consortium (BGTC), to expedite the development and manufacture of new AAV [adeno-associated virus] gene therapies to treat patients with rare diseases. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Gene Therapy 242

Gene Therapy Gene Development Manufacturing 242

Pharmaceutical Technology

MAY 16, 2023

The Foundation for the National Institutes of Health (FNIH) has announced its plans to prioritise eight rare diseases to provide industry standards for manufacturing, preclinical testing and product analytical testing for gene therapy development. This will include pairing up indications with manufacturers amongst the BGTC’s partners.

Gene Therapy 227

Gene Therapy Gene Research Clinical Trials 227

Bio Pharma Dive

FEBRUARY 6, 2024

The life sciences investor has backed a number of startups working on technologies for delivering and manufacturing cell and gene medicines.

Drug Delivery 200

Drug Delivery Life Science Gene Manufacturing 200

Cloudbyz

SEPTEMBER 10, 2023

The challenge of managing and securing sensitive data, including PHI and PII, is significant for life sciences organizations. Additionally, the consequences of data breaches can be severe for life sciences organizations. The challenge is further compounded by the need for fast and accurate analysis of data.

Life Science 90

Life Science Regulation Production Marketing 90

Drug Discovery World

AUGUST 4, 2023

CRADL’s first Seattle facility opened in 2021, in response to the city’s growing position as a key life sciences hub with significant start-up and entrepreneurial growth. In October, CRADL Philadelphia will open in uCity Square to support Philadelphia’s growth as a life sciences biohub.

Life Science 52

Life Science Gene Therapy Gene Editing In-Vivo 52

Drug Discovery World

MARCH 14, 2023

Life sciences membership organisation OBN (UK) will be holding in-person event BioTrinity 2023 in London on April 25-26. The conference will feature two tracks: ‘Scientific’, showcasing innovation across eight core therapy areas, and ‘Life Sciences Business & Investment’.

Life Science 52

Life Science Gene Therapy Gene Drugs 52

Pharmaceutical Technology

MARCH 10, 2023

On 10 March, the National Health Service Blood and Transplant (NHSBT) opened a new Clinical Biotechnology Centre (CBC) with the aim of improving the UK’s ability to develop and manufacture cell and gene therapies. The opening of this new facility plays into the UK government’s Life Sciences Industrial Strategy.

Gene Therapy 264

Gene Therapy Manufacturing Gene Clinical Trials 264

XTalks

DECEMBER 29, 2022

The life sciences and healthcare are among the biggest industries globally, and their significance was particularly highlighted during the past couple of years by the COVID-19 pandemic. Given the hyperfocus on the life sciences thanks to COVID, consumers appear to be more autonomous and vocal about their medical demands and choices.

Life Science 52

Life Science Gene Therapy Gene Manufacturing 52

XTalks

DECEMBER 20, 2023

In 2023, there were significant advancements and notable trends in the life sciences. Xtalks compiled a list of its top life science news and trends of 2023, which provided readers with the latest developments, information and expert insights across life science industries, including pharma, biotech and medical device.

Life Science 59

Life Science Clinical Trials Clinical Trials FDA Approval 59

XTalks

MARCH 8, 2022

On International Women’s Day, Xtalks is celebrating women’s leadership in the life sciences by highlighting some of the female leaders at the forefront of scientific discovery, as well as the continuing challenges of attaining more equitable representation. Challenges in Women’s Leadership.

Life Science 105

Life Science Gene Therapy DNA Vaccination 105

Bio Pharma Dive

MAY 6, 2021

Completion of the buyout eases concerns the arrangement might be held up by the FTC, which has signaled it will step up scrutiny of life sciences deals.

Gene Therapy 314

Gene Therapy Life Science Gene 314

Bio Pharma Dive

MAY 26, 2022

Bosley, who once led the CRISPR gene editing biotech, will become a venture partner at Advent Life Sciences, which backs a range of early-stage drug companies.

Gene Editing 255

Gene Editing Life Science Gene Drugs 255

XTalks

SEPTEMBER 29, 2022

The one-time administered gene therapy has also taken the title of being the world’s most expensive drug at $3 million. Hear more about the treatment and how the high prices of gene therapies can be alarming, but reimbursement programs are designed to pick up the costs. 7 that the CDC is closely watching.

Gene Therapy 52

Gene Therapy Life Science FDA Approval Gene 52

XTalks

APRIL 14, 2021

In this episode of the Xtalks Life Science Podcast, Sarah revisits two Parkinson’s biotech companies — Prevail Therapeutics and Voyager Therapeutics — to see what progress they’ve made in their gene therapy clinical development programs since April 2019. Parkinson’s and Melanoma Share an Amyloid Link, Says New Research.

Life Science 98

Life Science Gene Therapy Development Drugs 98

XTalks

AUGUST 31, 2022

Ayesha shared news about another significant FDA approval for a gene therapy to treat transfusion-dependent beta thalassemia. Bluebird bio was awarded the approval for its gene therapy Zynteglo (beti-cel), which is a one-time treatment for the rare blood disorder. Gene Therapy Zynteglo Wins Landmark FDA Approval for Beta Thalassemia.

Gene Therapy 52

Gene Therapy FDA Approval Life Science Gene 52

XTalks

SEPTEMBER 27, 2023

Poseida is a clinical-stage biopharmaceutical firm that utilizes its unique non-viral gene engineering methods to develop innovative cell and gene therapies. Subscribe to the Xtalks Life Science Podcast to never miss a new episode.

Life Science 59

Life Science Genetic Engineering Engineer Gene Therapy 59

BioTech 365

DECEMBER 14, 2020

Bionexus Gene Lab Corp to Webcast Live at Life Sciences Investor Forum December 17th Bionexus Gene Lab Corp to Webcast Live at Life Sciences Investor Forum December 17th Company invites individual and institutional investors, as well as advisors and analysts, … Continue reading →

Life Science 40

Life Science Gene 40

Medical Xpress

MARCH 21, 2023

An international study led by the Molecular Physiology Laboratory at the UPF Department of Medicine and Life Sciences (MELIS) identifies new genes that modulate the toxicity of the protein β-amyloid, responsible for causing Alzheimer's disease.

Protein 98

Protein Gene Life Science Research 98

Drug Discovery World

FEBRUARY 8, 2024

In 2023, DDW hosted a webinar, ‘A comprehensive guide to using adeno-associated virus (AAV) vectors in gene therapy’, supported by Azenta Life Sciences. AAV is optimal for gene therapy due to its efficiency and safety in humans; however, AAV processes can present obstacles for researchers. How is the titer determined?

Gene Therapy 59

Gene Therapy Gene Bioinformatics Life Science 59

XTalks

MAY 17, 2023

The Foundation for the National Institutes of Health (FNIH) announced this week that the Accelerating Medicines Partnership Bespoke Gene Therapy Consortium (AMP BGTC) has selected eight rare diseases for its clinical trial portfolio. As such, rare disease patients and their families often face little hope for effective treatments.

Gene Therapy 98

Gene Therapy Clinical Trials Clinical Trials Gene 98

Pharmaceutical Technology

DECEMBER 14, 2022

Merck and Synplogen have signed a non-binding Memorandum of Understanding (MoU) to expedite the development and manufacturing of viral vector-based gene therapy applications. The firms intend to merge their expertise to provide simplified viral vector gene therapy development, production and testing in Japan. By Cytiva Thematic.

Gene Therapy 130

Gene Therapy Gene Development Manufacturing 130

The Pharma Data

MAY 17, 2021

In fact, in recent times, tens of billions of dollars have flooded into the Midwest to accelerate life sciences innovation, and Illinois is ranked in the top 10 states in funding from the US National Institutes of Health. They provide a deep dive into the windy city’s standing in the life science space.

Life Science 52

Life Science Gene Therapy FDA Approval Gene 52

pharmaphorum

JULY 16, 2021

The Stevenage campus is one of GSK’s two main R&D sites, and also houses the Cell and Gene Therapy Catapult, set up in 2012 with government funding to bridge the gap between scientific research and full-scale commercialisation. The post GSK unveils plan for life sciences cluster at Stevenage campus appeared first on.

Life Science 59

Life Science Gene Therapy Gene Development 59

Drug Discovery World

OCTOBER 3, 2023

Earlier this year, DDW hosted a webinar, ‘A comprehensive guide to using adeno-associated virus (AAV) vectors in gene therapy’, supported by Azenta Life Sciences. AAV is optimal for gene therapy due to its efficiency and safety in humans; however, AAV processes can present obstacles for researchers.

Gene Therapy 52

Gene Therapy Gene Life Science Bioinformatics 52

Drug Discovery World

JULY 5, 2023

Join DDW for this exclusive free event , A Comprehensive Guide to Using Adeno-Associated Virus (AAV) Vectors in Gene Therapy, which is supported by Azenta Life Sciences. AAV is optimal for gene therapy due to its efficiency and safety in humans; however, AAV processes can present obstacles for researchers.

Gene Therapy 52

Gene Therapy Gene Bioinformatics Life Science 52

Drug Discovery World

JUNE 29, 2023

Join DDW for this exclusive free event , A Comprehensive Guide to Using Adeno-Associated Virus (AAV) Vectors in Gene Therapy, which is supported by Azenta Life Sciences. AAV is optimal for gene therapy due to its efficiency and safety in humans; however, AAV processes can present obstacles for researchers.

Gene Therapy 52

Gene Therapy Gene Bioinformatics Life Science 52

Drug Discovery World

JUNE 22, 2023

Join DDW for this exclusive free event , A Comprehensive Guide to Using Adeno-Associated Virus (AAV) Vectors in Gene Therapy, which is supported by Azenta Life Sciences. AAV is optimal for gene therapy due to its efficiency and safety in humans; however, AAV processes can present obstacles for researchers.

Gene Therapy 52

Gene Therapy Gene Bioinformatics Life Science 52

pharmaphorum

JUNE 3, 2021

The arrival of G7 health ministers to Oxford this week (Thursday 3 June) will shine a spotlight on Oxfordshire’s considerable achievements in the life sciences sector – and, according to the county’s Local Enterprise Partnership, there couldn’t be a better location globally for this summit to be held.

Life Science 52

Life Science Vaccination Vaccine Development 52

Drug Discovery World

JANUARY 10, 2024

New understanding of a gene that is linked to some forms of dementia and other age-related diseases gives scientists fresh hope that action can be taken against these diseases long before the onset of symptoms. The post Organoid research sheds light on gene mutation linked to dementia appeared first on Drug Discovery World (DDW).

Gene 59

Gene Research Gene Therapy Life Science 59

XTalks

JANUARY 3, 2024

Novartis and Voyager Therapeutics have struck a licensing deal that will see Novartis pay Voyager $100 million upfront to develop gene therapy candidates targeting Huntington’s disease (HD) and spinal muscular atrophy (SMA). The total value of the deal could potentially reach $1.2 Sandrock, Jr., MD, PhD, CEO of Voyager.

Gene Therapy 52

Gene Therapy Gene Licensing Licensing 52

BioTech 365

JUNE 9, 2021

Syros Pharmaceuticals to Present at JMP Securities 2021 Life Sciences Conference Syros Pharmaceuticals to Present at JMP Securities 2021 Life Sciences Conference CAMBRIDGE, Mass.–(BUSINESS

Life Science 52

Life Science Gene Medicine Development 52

BioPharma Reporter

JUNE 7, 2023

The Cell and Gene Therapy Catapult (CGT Catapult) has opened its facility in the Edinburgh BioQuarter, its first site in Scotland.

Life Science 59

Life Science Gene Therapy Gene Development 59

BioPharma Reporter

MARCH 30, 2023

Pharmaron Beijing Co Ltd says its Liverpool, UK based gene therapy CDMO has obtained a grant from the UK governmentâs life sciences innovation manufacturing fund (LSMIF) to expand its facilities.

Gene Therapy 52

Gene Therapy Gene Life Science Manufacturing 52

XTalks

MARCH 29, 2023

Manu explained how AI is helping to predict tumor mutations so that cell and gene therapies can be targeted to individual patient’s needs, realizing the true promise of “personalized medicine.” Subscribe to the Xtalks Life Science Podcast to never miss a new episode.

Life Science 52

Life Science Gene Therapy Gene Medicine 52